---

TL;DR

Isomorphic Labs, the Google DeepMind biotech spinoff founded by Nobel Prize winner Demis Hassabis, is preparing to launch human clinical trials for drugs designed entirely by AI using AlphaFold technology. The trials represent the first clinical validation of whether AI-designed molecules can deliver effective treatments at scale.

Key Facts

• Who: Isomorphic Labs (UK-based biotech spinoff of Google DeepMind)
• What: AI-designed drugs using AlphaFold 3 and proprietary IsoDDE platform entering human clinical trials
• When: Trials expected to begin by end of 2026; originally targeted late 2025
• Impact: First clinical test of whether AlphaFold-based drug discovery can produce working therapeutics

What Changed

On April 16, 2026, at WIRED Health in London, Isomorphic Labs president Max Jaderberg confirmed that the company is “gearing up to go into the clinic” with AI-designed drugs targeting oncology and immunology. The announcement marks a critical milestone for the 2021-founded biotech spinoff.

The timeline has shifted from the original target. CEO Demis Hassabis previously stated in 2024 that AI-designed drugs would enter clinical trials by the end of 2025. According to Reuters reporting from January 2026, the startup has delayed clinical trial initiation, though the company has since clarified it is actively preparing for trials by late 2026.

Isomorphic Labs has built what Jaderberg described as a “broad pipeline of new medicines” using DeepMind’s AlphaFold technology. The platform predicts protein structures and molecular interactions, enabling drug design at unprecedented speed and precision.

“The molecules we’re designing… we’ve engineered them to be very, very potent. You can take them at a much lower dose, and they’ll have lower side effects, off-target effects.” — Max Jaderberg, Isomorphic Labs President, WIRED Health London, April 2026

Why It Matters

The clinical trials represent the decisive test for AI drug discovery. AlphaFold has already demonstrated its predictive power — the platform has modeled over 200 million proteins and earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. But prediction success does not guarantee therapeutic efficacy.

Key developments leading to this moment:

Milestone	Date	Significance
AlphaFold 2 released	2020	Solved protein structure prediction challenge
AlphaFold open-sourced	2021	Available to researchers worldwide
AlphaFold 3 released	2024	Extended to DNA, RNA, and molecular interactions
IsoDDE platform announced	2025	Proprietary drug design engine, 2x AlphaFold 3 accuracy
$600M funding round	2024	Capital to advance clinical development

The company has established partnerships with Eli Lilly and Novartis to collaborate on AI drug discovery, while simultaneously developing its own pipeline in oncology and immunology. Isomorphic Labs appointed a chief medical officer in 2024 and has been building a clinical development team.

AlphaFold 3, released in May 2024, advanced beyond modeling isolated proteins to predicting interactions with DNA, RNA, and small molecules — precisely the capability required for drug design. Hassabis told WIRED at the time: “This is exactly what you need for drug discovery: You need to see how a small molecule is going to bind to a drug, how strongly, and also what else it might bind to.”

🔺 Scout Intel: What Others Missed

Confidence: high | Novelty Score: 85/100

While coverage focuses on the clinical milestone, the deeper signal is Isomorphic Labs’ strategic positioning: AlphaFold is transitioning from a scientific research tool to a validated drug discovery platform. The $600M funding round in 2024 — before any clinical data — indicates investor conviction that AlphaFold-based approaches will yield commercial therapeutics. However, the timeline delay from late 2025 to late 2026 suggests design complexity that proponents often understate. The partnership model with Eli Lilly and Novartis follows a dual-track strategy: license the technology to established pharma while building proprietary drugs in-house. If Phase III trials succeed, Isomorphic Labs becomes the first company to prove that AI-designed molecules can achieve therapeutic efficacy — not just faster discovery.

Key Implication: Pharmaceutical companies investing in AI drug discovery platforms face a binary outcome: Phase III success validates the entire approach, while failure would force reevaluation of computational drug design strategies across the industry.

What This Means

The clinical trials will determine whether AlphaFold’s predictive accuracy translates to therapeutic efficacy — a gap that has limited computational drug discovery for decades.

For pharmaceutical companies: Eli Lilly and Novartis have already committed to partnerships. Success would accelerate adoption of AI-assisted drug design across the industry. Traditional drug discovery costs an estimated $2.6 billion per approved drug with 10-15 year timelines; AI platforms promise significant compression of both metrics.

For investors: The $600M funding round suggests substantial pre-revenue valuation based on technology potential rather than clinical validation. Phase III outcomes will determine whether that valuation proves justified.

For patients: Isomorphic Labs claims its AI-designed molecules enable lower doses with reduced side effects due to improved target specificity. Clinical data will test this assertion.

What to watch: The specific therapeutic areas targeted — oncology and immunology — represent high-value, high-risk domains. Trial design, patient recruitment timelines, and interim efficacy data will signal whether AlphaFold-based drug discovery delivers on its promise.

Sources

• AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials — WIRED, April 24, 2026
• Isomorphic Labs Prepares to Launch Trials for AI-Designed Drugs — Clinical Trials Arena, July 2025
• Isomorphic Labs Timeline Update — Reuters, January 2026